RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

NCT03894215 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

211

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor strategic decision

Conditions

Cervical Cancer

Interventions

DRUG: AGEN2034
DRUG: AGEN1884

Sponsor

Agenus Inc.

Collaborators

[object Object]